Norbert Arnold

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9347411/publications.pdf

Version: 2024-02-01

174	10,778	36271	38368
papers	citations	51 h-index	95 g-index

181	181	181	14326
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Breast Cancer Risk Genes â€" Association Analysis in More than 113,000 Women. New England Journal of Medicine, 2021, 384, 428-439.	13.9	532
2	Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	1.1	513
3	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
4	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	3.8	390
5	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
6	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptorâ€"negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	9.4	309
7	Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Journal of Clinical Oncology, 2009, 27, 5887-5892.	0.8	292
8	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
9	Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. American Journal of Human Genetics, 2008, 82, 937-948.	2.6	257
10	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	1.5	244
11	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	1.1	224
12	RAD51 135Gâ†'C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. American Journal of Human Genetics, 2007, 81, 1186-1200.	2.6	217
13	Comprehensive analysis of 989 patients with breast or ovarian cancer providesBRCA1 andBRCA2 mutation profiles and frequencies for the German population. International Journal of Cancer, 2002, 97, 472-480.	2.3	198
14	Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene, 2005, 24, 1053-1065.	2.6	182
15	Prevalence ofBRCA1/2germline mutations in 21â€...401 families with breast and ovarian cancer. Journal of Medical Genetics, 2016, 53, 465-471.	1.5	179
16	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754.	0.4	169
17	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	0.8	152
18	Evaluation of SNPs inmiR-146a,miR196a2andmiR-499as low-penetrance alleles in German and Italian familial breast cancer cases. Human Mutation, 2010, 31, E1052-E1057.	1.1	147

#	Article	IF	Citations
19	Gene panel testing of 5589 <scp>BRCA</scp>1/2â€negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. Cancer Medicine, 2018, 7, 1349-1358.	1.3	126
20	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125
21	A genetic variant in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk. Breast Cancer Research and Treatment, 2010, 121, 693-702.	1.1	115
22	Overrepresentation of 3q and 8q material and loss of 18q material are recurrent findings in advanced human ovarian cancer. , 1996, 16, 46-54.		111
23	Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. Human Molecular Genetics, 2016, 25, 2256-2268.	1.4	106
24	Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genetics, 2013, 9, e1003173.	1.5	105
25	A highly sensitive, fast, and economical technique for mutation analysis in hereditary breast and ovarian cancers. , 1999, 14, 333-339.		104
26	Identification of brain- and bone-specific breast cancer metastasis genes. Cancer Letters, 2009, 276, 212-220.	3.2	104
27	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Human Mutation, 2019, 40, 1557-1578.	1.1	102
28	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2009, 18, 4442-4456.	1.4	99
29	Is the Ki-67 labelling index ready for clinical use?. Annals of Oncology, 2011, 22, 500-502.	0.6	98
30	Role of Cannabinoid Receptor CB2 in HER2 Pro-oncogenic Signaling in Breast Cancer. Journal of the National Cancer Institute, 2015, 107, djv077.	3.0	98
31	Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 2014, 16, 3419.	2.2	97
32	Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer. PLoS Biology, 2011, 9, e1001199.	2.6	91
33	A variant affecting a putative miRNA target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women. Carcinogenesis, 2009, 30, 59-64.	1.3	90
34	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	2.2	88
35	Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation. Cancer, 2001, 91, 534-540.	2.0	87
36	Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer. PLoS Genetics, 2010, 6, e1001183.	1.5	85

#	Article	IF	Citations
37	Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. BMC Cancer, 2018, 18, 265.	1.1	84
38	Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. International Journal of Cancer, 2009, 124, 1727-1735.	2.3	83
39	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	1.1	82
40	Identification of specificBRCA1 andBRCA2 variants by DHPLC. Human Mutation, 2000, 16, 345-353.	1.1	81
41	Limited relevance of theCHEK2gene in hereditary breast cancer. International Journal of Cancer, 2004, 110, 320-325.	2.3	79
42	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers. Breast Cancer Research, 2012, 14, R33.	2.2	78
43	BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. Breast Cancer Research, 2018, 20, 7.	2.2	78
44	Genomic reorganization and disrupted chromosomal synteny in the siamang (Hylobates syndactylus) revealed by fluorescence in situ hybridization. American Journal of Physical Anthropology, 1995, 97, 37-47.	2.1	76
45	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2011, 13, R110.	2.2	71
46	LargeBRCA1 gene deletions are found in 3% of German high-risk breast cancer families. Human Mutation, 2004, 24, 534-534.	1.1	69
47	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321.	1.4	68
48	Non-radioactive Labeling and Detection of Nucleic Acids. III Applications of the Digoxigenin System. Biological Chemistry Hoppe-Seyler, 1990, 371, 939-952.	1.4	58
49	Simian Y Chromosomes: species-specific rearrangements of DAZ, RBM, and TSPY versus contiguity of PAR and SRY. Mammalian Genome, 1998, 9, 226-231.	1.0	58
50	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	2.2	57
51	Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer. Carcinogenesis, 2006, 27, 2201-2208.	1.3	54
52	Mutation analysis of p53 in ovarian tumors by DHPLC. Journal of Proteomics, 2001, 47, 73-81.	2.4	53
53	SNPs in ultraconserved elements and familial breast cancer risk. Carcinogenesis, 2008, 29, 351-355.	1.3	53
54	Genetic Characteristics of the Human Hepatic Stellate Cell Line LX-2. PLoS ONE, 2013, 8, e75692.	1.1	53

#	Article	IF	Citations
55	The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium. Journal of Medical Genetics, 2018, 55, 15-20.	1.5	50
56	Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer. Human Mutation, 2011, 32, E2176-E2188.	1.1	49
57	An Integrated Clinical-Genomics Approach Identifies a Candidate Multi-Analyte Blood Test for Serous Ovarian Carcinoma. Clinical Cancer Research, 2007, 13, 458-466.	3.2	48
58	Interaction of Werner and Bloom syndrome genes with p53 in familial breast cancer. Carcinogenesis, 2005, 27, 1655-1660.	1.3	47
59	Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657.	1.1	47
60	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	1.5	47
61	Neutrophil Gelatinase-Associated Lipocalin (NGAL) Predicts Response to Neoadjuvant Chemotherapy and Clinical Outcome in Primary Human Breast Cancer. PLoS ONE, 2012, 7, e45826.	1.1	47
62	Comparative High-Resolution Mapping of Human and Primate Chromosomes by Fluorescence in Situ Hybridization. Genomics, 1993, 18, 381-386.	1.3	46
63	Analysis of 30 Putative BRCA1 Splicing Mutations in Hereditary Breast and Ovarian Cancer Families Identifies Exonic Splice Site Mutations That Escape In Silico Prediction. PLoS ONE, 2012, 7, e50800.	1.1	45
64	Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management. Breast Cancer Research and Treatment, 2012, 134, 1229-1239.	1.1	44
65	Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer. Breast Cancer Research, 2019, 21, 55.	2.2	44
66	Progression-Free Survival in Ovarian Cancer Is Reflected in Epigenetic DNA Methylation Profiles. Oncology, 2011, 80, 12-20.	0.9	43
67	Comparative mapping of DNA probes derived from the Vϊº immunoglobulin gene regions on human and great ape chromosomes by fluorescence in situ hybridization. Genomics, 1995, 26, 147-150.	1.3	42
68	Genomic Organization and Molecular Characterization of a Gene Encoding HsPXF, a Human Peroxisomal Farnesylated Protein. Genomics, 1997, 45, 200-210.	1.3	42
69	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	2.2	42
70	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2011, 103, 105-116.	3.0	40
71	Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer. Oncotarget, 2016, 7, 47565-47575.	0.8	40
72	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.4	39

#	Article	IF	Citations
73	An easy and reliable procedure of microdissection technique for the analysis of chromosomal breakpoints and marker chromosomes. Chromosome Research, 1999, 7, 355-362.	1.0	38
74	S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours. Geburtshilfe Und Frauenheilkunde, 2013, 73, 874-889.	0.8	38
75	Genetic Imbalances in Precursor Lesions of Endometrial Cancer Detected by Comparative Genomic Hybridization. American Journal of Pathology, 2000, 156, 1827-1833.	1.9	37
76	Association of the VariantsCASP8D302H andCASP10V410I with Breast and Ovarian Cancer Risk inBRCA1andBRCA2Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2859-2868.	1.1	37
77	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. American Journal of Human Genetics, 2015, 97, 22-34.	2.6	37
78	Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors. Journal of Leukocyte Biology, 2020, 107, 1081-1095.	1.5	35
79	Identification of candidate tumour suppressor gene loci for Hodgkin and Reedâ€Sternberg cells by characterisation of homozygous deletions in classical Hodgkin lymphoma cell lines. British Journal of Haematology, 2008, 142, 916-924.	1.2	34
80	Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers. Human Mutation, 2012, 33, 690-702.	1.1	34
81	High expression of crystallin Î±B represents an independent molecular marker for unfavourable ovarian cancer patient outcome and impairs TRAILâ€and cisplatinâ€induced apoptosis in human ovarian cancer cells. International Journal of Cancer, 2013, 132, 2820-2832.	2.3	34
82	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	1.1	34
83	Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer. Endocrine-Related Cancer, 2007, 14, 267-277.	1.6	33
84	Induction of Human Î²-defensins and Psoriasin in Vulvovaginal Human Papillomavirusâ€“Associated Lesions. Journal of Infectious Diseases, 2011, 204, 391-399.	1.9	33
85	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Human Molecular Genetics, 2011, 20, 4732-4747.	1.4	32
86	Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance. International Journal of Cancer, 2020, 146, 999-1009.	2.3	32
87	The functional genetic variant Ile646Val located in the kinase binding domain of the A-kinase anchoring protein 10 is associated with familial breast cancer. Carcinogenesis, 2006, 28, 423-426.	1.3	31
88	Quantifying cell free DNA in urine: comparison between commercial kits, impact of gender and inter-individual variation. BioTechniques, 2018, 64, 225-230.	0.8	31
89	Comparison of gene expression data from human and mouse breast cancers: Identification of a conserved breast tumor gene set. International Journal of Cancer, 2007, 121, 683-688.	2.3	30
90	High resolution copy number analysis of IRF4 translocationâ€positive diffuse large Bâ€cell and follicular lymphomas. Genes Chromosomes and Cancer, 2013, 52, 150-155.	1.5	30

#	Article	IF	Citations
91	Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer. International Journal of Cancer, 2014, 135, 2352-2361.	2.3	29
92	Screening for large rearrangements of theBRCA1gene in German breast or ovarian cancer families using semi-quantitative multiplex PCR method. Human Mutation, 2003, 22, 103-104.	1.1	28
93	GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma. British Journal of Haematology, 2009, 144, 317-331.	1.2	28
94	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	2.3	28
95	Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity. Oncogene, 2007, 26, 2685-2694.	2.6	27
96	Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. British Journal of Cancer, 2012, 106, 2016-2024.	2.9	27
97	Genetic background of different cancer cell lines influences the gene set involved in chromosome 8 mediated breast tumor suppression. Genes Chromosomes and Cancer, 2006, 45, 612-627.	1.5	26
98	Lowâ€risk variants FGFR2, TNRC9 and LSP1 in German familial breast cancer patients. International Journal of Cancer, 2010, 126, 2858-2862.	2.3	26
99	Combined treatment with TRAIL and PPARÎ³ ligands overcomes chemoresistance of ovarian cancer cell lines. Journal of Cancer Research and Clinical Oncology, 2011, 137, 875-886.	1.2	26
100	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	2.2	26
101	The CpG island methylator phenotype in breast cancer is associated with the lobular subtype. Epigenomics, 2015, 7, 187-199.	1.0	26
102	Mammary fibroblasts regulate morphogenesis of normal and tumorigenic breast epithelial cells by mechanical and paracrine signals. Cancer Letters, 2012, 325, 175-188.	3.2	25
103	Reverse painting of microdissected chromosome 19 markers in ovarian carcinoma identifies a complex rearrangement map. Genes Chromosomes and Cancer, 2009, 48, 184-193.	1.5	23
104	A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1362-1370.	1.1	23
105	A dendritic cell based hybrid cell vaccine generated by electrofusion for immunotherapy strategies in HNSCC. Auris Nasus Larynx, 2004, 31, 149-153.	0.5	22
106	Identification of aDMBT1polymorphism associated with increased breast cancer risk and decreased promoter activity. Human Mutation, 2010, 31, 60-66.	1.1	22
107	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	1.1	22
108	The Impact of Electrical Charge on the Viability and Physiology of Dendritic Cells.. Scandinavian Journal of Immunology, 2005, 62, 399-406.	1.3	21

#	Article	IF	Citations
109	Recurrent loss, but lack of mutations, of the SMARCB1 tumor suppressor gene in T-cell prolymphocytic leukemia with TCL1Aâ€"TCRAD juxtaposition. Cancer Genetics and Cytogenetics, 2009, 192, 44-47.	1.0	21
110	Performance of Breast Cancer Polygenic Risk Scores in 760 FemaleCHEK2Germline Mutation Carriers. Journal of the National Cancer Institute, 2021, 113, 893-899.	3.0	21
111	Highly comprehensive karyotype analysis by a combination of spectral karyotyping (SKY), microdissection, and reverse painting (SKY-MD). Chromosome Research, 2001, 9, 395-402.	1.0	20
112	The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2009, 101, 1456-1460.	2.9	19
113	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	2.9	19
114	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	5.8	19
115	Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	3.0	19
116	SNiPER: a novel hypermethylation biomarker panel for liquid biopsy based early breast cancer detection. Oncotarget, 2019, 10, 6494-6508.	0.8	19
117	Arrayâ€CGH analysis of microdissected chromosome 19 markers in ovarian carcinoma identifies candidate target genes. Genes Chromosomes and Cancer, 2010, 49, 1046-1053.	1.5	18
118	Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk. Breast Cancer Research and Treatment, 2011, 127, 549-554.	1.1	18
119	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
120	Spectrum of genetic variants of BRCA1 and BRCA2 in a German single center study. Archives of Gynecology and Obstetrics, 2017, 295, 1227-1238.	0.8	18
121	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	1.1	18
122	Criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the Classification of Germline Sequence Variants in Risk Genes for Hereditary Breast and Ovarian Cancer. Geburtshilfe Und Frauenheilkunde, 2020, 80, 410-429.	0.8	18
123	Establishing a control population to screen for the occurrence of nineteen unclassified variants in the BRCA1 gene by denaturing high-performance liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 782, 99-104.	1.2	17
124	Recurrent loss of the Y chromosome and homozygous deletions within the pseudoautosomal region 1: association with male predominance in mantle cell lymphoma. Haematologica, 2008, 93, 949-950.	1.7	17
125	ADAM17 inhibition enhances platinum efficiency in ovarian cancer. Oncotarget, 2018, 9, 16043-16058.	0.8	17
126	Ten novelBRCA1 andBRCA2 mutations in breast and/or ovarian cancer families from northern Germany. Human Mutation, 2000, 16, 529-530.	1.1	16

#	Article	IF	Citations
127	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	1.1	16
128	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). British Journal of Cancer, 2009, 101, 2048-2054.	2.9	15
129	An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2008, 99, 974-977.	2.9	14
130	Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events. Journal of Physical Education and Sports Management, 2017, 3, a001677.	0.5	14
131	Comparison of comparative genomic hybridization and interphase fluorescence in situ hybridization in ovarian carcinomas. Cancer Genetics and Cytogenetics, 2000, 122, 7-12.	1.0	12
132	Combination of Enzastaurin and Pemetrexed Inhibits Cell Growth and Induces Apoptosis of Chemoresistant Ovarian Cancer Cells Regulating Extracellular Signal-Regulated Kinase 1/2 Phosphorylation. Translational Oncology, 2009, 2, 164-IN1.	1.7	12
133	Prognostic Value of Human Epidermal Growth Factor Receptor 2 (Her-2)/neu in Patients With Advanced Ovarian Cancer Treated With Platinum/Paclitaxel as First-Line Chemotherapy: A Retrospective Evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. International Journal of Gynecological Cancer, 2009, 19, 109-115.	1.2	12
134	Chromosomal mosaicisms in prenatal diagnosis: correlation with first trimester screening and clinical outcome. Journal of Perinatal Medicine, 2012, 40, 215-23.	0.6	12
135	Evaluation of Potentially Predictive Markers for Anti-Angiogenic Therapy with Sunitinib in Recurrent Ovarian Cancer Patients. Translational Oncology, 2013, 6, 305-310.	1.7	12
136	Coincident PTCH and BRCA1 Germline Mutations in a Patient with Nevoid Basal Cell Carcinoma Syndrome and Familial Breast Cancer. Journal of Investigative Dermatology, 2001, 116, 472-474.	0.3	11
137	Nuclear receptor coregulator SNP discovery and impact on breast cancer risk. BMC Cancer, 2009, 9, 438.	1.1	11
138	A variant affecting miRNAs binding in the circadian gene Neuronal PAS domain protein 2 (NPAS2) is not associated with breast cancer risk. Breast Cancer Research and Treatment, 2011, 127, 769-775.	1.1	11
139	CDH1 mutation screen in a BRCA1/2-negative familial breast-/ovarian cancer cohort. Archives of Gynecology and Obstetrics, 2018, 297, 147-152.	0.8	11
140	ADAM17â€”A Potential Blood-Based Biomarker for Detection of Early-Stage Ovarian Cancer. Cancers, 2021, 13, 5563.	1.7	11
141	Prevalence of Cancer Predisposition Germline Variants in Male Breast Cancer Patients: Results of the German Consortium for Hereditary Breast and Ovarian Cancer. Cancers, 2022, 14, 3292.	1.7	11
142	Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women. BMC Cancer, 2019, 19, 787.	1.1	10
143	Linking pre-existing biorepositories for medical research: the PopGen 2.0 Network. Journal of Community Genetics, 2019, 10, 523-530.	0.5	10
144	A network of clinically and functionally relevant genes is involved in the reversion of the tumorigenic phenotype of MDA-MB-231 breast cancer cells after transfer of human chromosome 8. Oncogene, 2005, 24, 869-879.	2.6	9

#	Article	IF	Citations
145	Strong evidence that the common variant S384F in BRCA2has no pathogenic relevance in hereditary breast cancer. Breast Cancer Research, 2005, 7, R775-9.	2.2	9
146	Proof of partial imbalances 6q and 11q due to maternal complex balanced translocation analyzed by microdissection of multicolor labeled chromosomes (FISH-MD) in a patient with Dandy-Walker variant. Cytogenetic and Genome Research, 2006, 114, 235-239.	0.6	9
147	Association of death receptor 4 variant (683A>C) with ovarian cancer risk in BRCA1 mutation carriers. International Journal of Cancer, 2012, 130, 1314-1318.	2.3	9
148	Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3. Archives of Gynecology and Obstetrics, 2013, 288, 173-182.	0.8	9
149	Alteration of STR profiles in ovarian carcinoma cells during primary culture. Archives of Gynecology and Obstetrics, 2016, 294, 369-376.	0.8	8
150	Changes in classification of genetic variants in BRCA1 and BRCA2. Archives of Gynecology and Obstetrics, 2018, 297, 279-280.	0.8	8
151	Characterization of two supernumerary marker chromosomes in a patient with signs of Klinefelter syndrome, mild facial anomalies, and severe speech delay. American Journal of Medical Genetics, Part A, 2006, 140A, 488-495.	0.7	7
152	Isolated trisomy 7q21.2-31.31 resulting from a complex familial rearrangement involving chromosomes 7, 9 and 10. Molecular Cytogenetics, 2011, 4, 28.	0.4	7
153	Simultaneous Congener-Specific Determination of Selected Organochlorine Compounds and Nitro Musks in Human Whole Blood Samples by Solid-Phase Extraction and Capillary Gas Chromatography with Electron Capture Detection. Journal of Analytical Toxicology, 2005, 29, 110-117.	1.7	6
154	Polymorphisms in BRCA2 resulting in aberrant codon-usage and their analysis on familial breast cancer risk. Breast Cancer Research and Treatment, 2009, 118, 407-413.	1.1	6
155	Breakpoint characterization of the der(19)t(11;19)(q13;p13) in the ovarian cancer cell line SKOVâ€3. Genes Chromosomes and Cancer, 2013, 52, 512-522.	1.5	6
156	Oocyte morphology on day 0 correlates with aneuploidy as detected by polar body biopsy and FISH. Archives of Gynecology and Obstetrics, 2014, 289, 445-450.	0.8	6
157	Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers. BMC Cancer, 2022, 22, .	1.1	6
158	Gene Expression Profiling of Epithelial Ovarian Cancer. Current Genomics, 2006, 7, 115-135.	0.7	4
159	Allelic loss analysis by denaturing high-performance liquid chromatography and electrospray ionization mass spectrometry. Human Mutation, 2007, 28, 303-311.	1.1	4
160	Premature ovarian failure in a patient with a complex chromosome rearrangement involving the critical region Xq24, characterized by analysis using fluorescence in situ hybridization by chromosome microdissection. Fertility and Sterility, 2007, 88, 1677.e9-1677.e13.	0.5	3
161	Frequent translocations of 11q13.2 and 19p13.2 in ovarian cancer. Genes Chromosomes and Cancer, 2014, 53, 447-453.	1.5	3
162	Head-to-head comparison of the impact of Aurora A, Aurora B, Repp86, CDK1, CDK2 and Ki67 expression in two of the most relevant gynaecological tumor entities. Archives of Gynecology and Obstetrics, 2016, 294, 813-823.	0.8	3

#	Article	IF	Citations
163	Sham-controlled implantation after preimplantation genetic screening by polar body biopsy and FISH. Archives of Gynecology and Obstetrics, 2014, 289, 439-444.	0.8	2
164	The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers. International Journal of Cancer, 2019, 144, 1761-1763.	2.3	2
165	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	1.6	2
166	BRCA1/2 mutation prevalence in triple-negative breast cancer patients without family history of breast and ovarian cancer.. Journal of Clinical Oncology, 2016, 34, 1090-1090.	0.8	2
167	Detection of Cancer Mutations by Urine Liquid Biopsy as a Potential Tool in the Clinical Management of Bladder Cancer Patients. Cancers, 2022, 14, 969.	1.7	2
168	RNA based individualized drug selection in breast cancer patients without patient-matched normal tissue. Oncotarget, 2018, 9, 32362-32372.	0.8	1
169	Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation. Cancer, 2001, 91, 534-540.	2.0	1
170	A Fast, Highly Sensitive and Cheap Tool for Mutation Analysis of Complex Genes. Disease Markers, 1999, 15, 118-118.	0.6	0
171	Conservative preimplantation genetic diagnosis (CPGD). Fertility and Sterility, 2002, 78, S180.	0.5	0
172	Reply to letter by Dr. G. Corso. Archives of Gynecology and Obstetrics, 2018, 297, 1069-1069.	0.8	0
173	An Activating Mutation (Ser525Pro) within the Transactivation Domain of REL in Two Patients with Human B-Cell Lymphomas Enhances RELâ€™s In Vitro Transforming Activity.. Blood, 2005, 106, 2617-2617.	0.6	0
174	NGS-based multi-gene panel analysis in BRCA1/2-negative breast and ovarian cancer families.. Journal of Clinical Oncology, 2017, 35, 1526-1526.	0.8	0